- Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) have initiated a Phase 1 study to evaluate the safety, tolerability, and immunogenicity of a next-generation COVID-19 vaccine candidate.
- The next-gen vaccine candidate aims to enhance SARS-CoV-2 T cell responses and potentially broaden protection against COVID-19.
- The candidate, dubbed BNT162b4, includes T cell antigen mRNA encoding for SARS-CoV-2 non-spike proteins and will be evaluated in combination with the companies’ omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine.
- Related: Pfizer/BioNTech Updated Omicron Adapted COVID-19 Vaccine Shows 4-Fold Higher Neutralizing Activity.
- BNT162b4 will be evaluated in approximately 180 healthy adults between 18-55 years who have received at least three doses of an mRNA-based COVID-19 vaccine.
- The trial will explore different dose levels of BNT162b4 administered in combination with a 30-µg dose of the companies’ omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine. It will be compared to administering a 30-µg dose of the omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as a booster.
- This study is part of the companies’ long-term and multi-pronged scientific strategy to generate more robust, longer-lasting, and broader immune responses against COVID-19.
- Price Action: BNTX stock closed at $164.90 on Wednesday, and PFE shares are up 0.10% at $48.10 during the premarket session on the last check Thursday.
Victoria’s Secret Returns To ‘Sexy’ Roots After Inclusive Branding Fails To Boost Sales
The sales slump followed the company's decision to establish a predominantly female board of directors and discontinue the use of the famous "Angels" supermodels
